Delaware
|
0-32353
|
84-1475642
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Date: January 18, 2007 |
ZIOPHARM
Oncology, Inc.:
(Registrant)
|
|
|
|
|
By: | /s/ Richard E. Bagley | |
Richard E. Bagley,
President,
Chief
Operating Officer and Chief Financial
Officer
|